TABLE 3.

Plasma and urine metabolic ratios of EFV in healthy volunteers after a single 100-mg oral dose of EFV at baseline (control) and after treatment with voriconazole to steady state

PK parameter	Mean ± SD for group:		% mean change	P value
	Control	Voriconazoleb
Plasma AUC metabolic ratio (AUC of EFV/AUC of metabolite)
8-OHEFV
0–12 h	4.6 ± 3.1	12.0 ± 6.3	189	<0.001
0–24 h	4.4 ± 3.1	10.7 ± 5.6	171	<0.001
0–48 h	4.1 ± 3.3	9.1 ± 5.1	146	<0.001
7-OHEFV
0–12 h	156 ± 206	133 ± 126	18	0.09
0–24 h	137 ± 209	109 ± 101	17	0.09
0–48 h	126 ± 209	93 ± 83	16	0.09
Di-OHEFV
0–12 h	12.7 ± 10.2	56.2 ± 39.9	383	<0.001
0–24 h	11.9 ± 10.7	48.5 ± 35.7	343	<0.001
0–48 h	11.5 ± 12.6	40.2 ± 31.5	291	<0.001
0- to 48-h molar ratio (Ae of metabolite/Ae of EFV)a
8-OHEFV/EFV	684 ± 386	304 ± 158	−49.1	<0.001
7-OHEFV/EFV	169 ± 119	110 ± 62	−21.4	<0.001
Di-OHEFV/EFV	516 ± 285	164 ± 90	−62.1	<0.001
Di-OHEFV/8-OHEFV	0.8 ± 0.2	0.6 ± 0.5	−29.5	<0.001
8- + di-OHEFV/EFV	1,200 ± 655	468 ± 240	−55.3	<0.001

^aRatios are large because EFV excreted unchanged was relatively small.

^bNote that the effect of voriconazole on plasma MRs was larger than that on urine MRs.